Get the Stockscreener App
0.8801
1.58%
0.0089
Icecure Medical Ltd stock is traded at $0.8801, with a volume of 305.99K.
It is up +1.58% in the last 24 hours and down -10.20% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$0.8712
Open:
$0.8876
24h Volume:
305.99K
Relative Volume:
0.14
Market Cap:
$60.79M
Revenue:
$3.67M
Net Income/Loss:
$-13.83M
P/E Ratio:
-3.1432
EPS:
-0.28
Net Cash Flow:
$-10.79M
1W Performance:
-11.50%
1M Performance:
-10.20%
6M Performance:
-21.33%
1Y Performance:
+56.89%
1-Day Range:
$0.8641
$0.8976
1-Week Range:
$0.8641
$1.01
52-Week Range:
$0.5101
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
0.8849 | 60.07M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
131.73 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.87 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
366.35 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.23 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.35 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Icecure Medical Ltd Stock (ICCM) Latest News
Can a trend reversal in IceCure Medical Ltd lead to recoveryJuly 2025 Momentum & Reliable Intraday Trade Plans - newser.com
What momentum indicators show for IceCure Medical Ltd stock2025 Trading Volume Trends & Entry Point Confirmation Signals - newser.com
Pattern recognition hints at IceCure Medical Ltd upsideNew Guidance & Free Accurate Trade Setup Notifications - newser.com
New FDA-Approved Breast Cancer Treatment Freezes Tumors Instead Of Removing Them - essence.com
Brookline Capital Management Predicts IceCure Medical Q3 Earnings - MarketBeat
IceCure Medical to Attend the 2025 Maxim Growth Summit - WV News
IceCure Medical (NASDAQ:ICCM) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
IceCure Medical : Company Presentation - MarketScreener
FDA Authorizes ProSense Cryoablation System for Early-Stage Breast Cancer in Older Women - Medical Dialogues
IceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.50 - MarketBeat
HC Wainwright & Co. Maintains IceCure Medical (ICCM) Buy Recommendation - Nasdaq
IceCure Medical stock price target raised to $2.50 from $2.00 at H.C. Wainwright - Investing.com
IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright - TipRanks
ICCM: HC Wainwright & Co. Boosts Price Target to $2.50, Maintains Buy Rating | ICCM Stock News - GuruFocus
IceCure ProSense Cryoablation Receives FDA Marketing Authorization for Treating Low-Risk Breast Cancer in Women Aged 70+ - Imaging Technology News
Icecure gets FDA nod for Prosense cryoablation in breast cancer - BioWorld MedTech
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment - Yahoo Finance
Transcript : IceCure Medical LtdSpecial Call - MarketScreener
What MACD and RSI say about IceCure Medical Ltd2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Chart based exit strategy for IceCure Medical LtdJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
IceCure Medical Ltd’s volatility index tracking explained2025 Valuation Update & Growth-Oriented Investment Plans - newser.com
IceCure Medical Ltd stock prediction for this weekMarket Performance Recap & Reliable Breakout Forecasts - newser.com
What drives EcoSynthetix Inc 0Y8 stock priceStock Split Announcements & Rapid Wealth Building Tips - earlytimes.in
IceCure Medical Ltd Stock Analysis and ForecastPrice-to-Book Ratio Updates & Your Free Entry to Smart Investing Starts Here - earlytimes.in
IceCure Receives FDA Marketing Authorization for ProSense(R) Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - MarketScreener
Using portfolio simulators with IceCure Medical Ltd includedJuly 2025 Retail & Safe Capital Investment Plans - newser.com
Key metrics from IceCure Medical Ltd’s quarterly dataQuarterly Trade Summary & Step-by-Step Trade Execution Guides - newser.com
Developing predictive dashboards with IceCure Medical Ltd data2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Is IceCure Medical Ltd stock attractive for growth ETFsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - newser.com
IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Down 49.8% in September - MarketBeat
IceCure Medical Surges on FDA Authorization for Breast Cancer Treatment - StocksToTrade
IceCure Medical Ltd. (NASDAQ:ICCM) Receives Average Rating of "Buy" from Analysts - MarketBeat
IceCure Medical Ltd. Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - MarketScreener
FDA approves IceCure cryoablation for breast cancer - MassDevice
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - Lelezard
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care - Lelezard
ICCM Gains FDA Approval for ProSense Cryoablation System in Cert - GuruFocus
IceCure Receives FDA Marketing Authorization for ProSense® Cryoa - GuruFocus
Icecure Medical stock surges after FDA approves breast cancer treatment - Investing.com
IceCure Medical Gets FDA Approval for ProSense Breast Cancer Treatment; Shares Rise - MarketScreener
IceCure Medical receives FDA marketing authorizationf or ProSense cryoablation - TipRanks
Full technical analysis of IceCure Medical Ltd stock2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
46,000 U.S. Women: IceCure Receives FDA Marketing Authorization for ProSense®; CPT III Covers $3,800 - Stock Titan
Detecting price anomalies in IceCure Medical Ltd with AILong Setup & Low Risk High Win Rate Picks - newser.com
Visualizing IceCure Medical Ltd stock with heatmapsJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Icecure's Prosense At the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer - MarketScreener
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented - Barchart.com
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):